KRAS vs NRAS vs HRAS (2026): Key Differences, Mutations, and Targeted Treatments

Article Summary

• G12C is a specific KRAS mutation (glycine → cysteine at position 12)

• It is the first KRAS* mutation successfully targeted by drugs

• Found mainly in lung cancer

• Enables precision therapy with KRAS inhibitors

• Not all KRAS mutations are equal—G12C is uniquely druggable.

*Note: The KRAS gene (Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) is an oncogene that encodes a small GTPase transductor protein called KRAS.

The RAS gene family—including KRAS, NRAS, and HRAS—plays a central role in cancer biology. These genes encode small GTPase proteins that act as molecular switches controlling cell growth, survival, and differentiation.

When mutated, they become permanently “on”, driving uncontrolled cancer growth.

Among these, KRAS mutations are the most common and clinically actionable, especially with the recent breakthrough targeting a specific mutation known as G12C.

To truly understand modern cancer treatment, you need to understand what G12C means—and why it changed oncology.

What Are KRAS, NRAS, and HRAS?

All three belong to the RAS (Rat Sarcoma Virus) oncogene family, but differ in:

• Mutation frequency
• Cancer type association
• Druggability
• Clinical impact

They regulate key pathways such as:

• MAPK/ERK pathway
• PI3K/AKT pathway.

What Is G12C? (Critical Concept Explained)

G12C is a specific mutation in the KRAS gene.

It describes a precise amino acid substitution:

G12C:\ Glycine_{12} \rightarrow Cysteine

What this means:

• “G” (glycine) = original amino acid

• “12” = position in the KRAS protein

• “C” (cysteine) = new amino acid after mutation

So, G12C = glycine at position 12 replaced by cysteine

---

Why G12C Is So Important

Not all KRAS mutations are equal.

What makes G12C unique:

1. It creates a druggable “pocket”

The cysteine residue allows drugs to bind covalently to KRAS—something not possible with most other mutations.

2. It locks KRAS in an active state

Like other KRAS mutations, G12C keeps the protein:

• Permanently “on”

• Continuously signaling cell growth

3. It enabled the first successful KRAS inhibitors

For decades, KRAS was considered “undruggable”—until G12C changed that.

---

Where Is KRAS G12C Found?

G12C is most common in:

• Non-small cell lung cancer (NSCLC) (~13%)

• Colorectal cancer (~3–5%)

• Rare in pancreatic cancer (which more often has G12D)

---

KRAS G12C Targeted Therapy (2026 Breakthrough)

Two major drugs now directly target KRAS G12C:

• Sotorasib

• Adagrasib

How These Drugs Work

They:

• Bind specifically to the mutant cysteine

• Lock KRAS in its inactive state

• Shut down cancer signaling

👉 This is a precision therapy milestone

---

Why G12C Doesn’t Apply to All KRAS Mutations

KRAS mutations vary:

• G12C → druggable

• G12D → common but harder to target

• G13D → different biology

👉 Most KRAS mutations still lack effective direct inhibitors

This is why:

• G12C patients have targeted options

• Others rely on chemo, immunotherapy, or trials

---

Integrating G12C into KRAS vs NRAS vs HRAS

KRAS (Now Divided by Mutation Type)

KRAS is no longer a single category.

KRAS G12C

• Targetable

• Found mainly in lung cancer

• Treated with KRAS inhibitors

Non-G12C KRAS (e.g., G12D)

• Not yet easily druggable

• Common in pancreatic cancer

• Treated with:

  • Chemotherapy

  • Clinical trials

---

NRAS (No G12C Equivalent Impact)

• Mutations usually occur at Q61

• No direct inhibitors yet

• Treated mainly with:

  • Immunotherapy

  • MEK inhibitors

---

HRAS (Different Targeting Strategy)

• Does not rely on G12C

• Instead depends on farnesylation

• Targeted by:

  • Tipifarnib

---

Clinical Impact of G12C (Why Patients Should Care)

If your tumor has KRAS G12C:

• You may qualify for targeted therapy

• You may avoid some chemotherapy

• You may benefit from combination strategies:

  • KRAS inhibitor + immunotherapy

If you do NOT have G12C:

• Treatment depends on:

  • Other mutations

  • Biomarkers

  • Standard therapies

---

The Future Beyond G12C

G12C is just the beginning. Emerging research is targeting:

• G12D (pancreatic cancer)

• Pan-RAS inhibitors

• KRAS vaccines

👉 The goal: make all KRAS mutations druggable.

Final Word

RAS mutations are not interchangeable.

Understanding the difference between KRAS, NRAS, and HRAS can:

• Predict treatment response
• Guide targeted therapy
• Influence survival outcomes

In modern oncology, genetics is destiny—but only if you know how to use it.